Hetero Biopharma launches ‘RILAST,’ the biosimilar Rituximab in Georgia.
Hetero Biopharma, the biologics arm of Hetero, launched the biosimilar Rituximab under the brand name ‘RILAST’ in Georgia with its strategic business partner M/s Zandra life sciences at Tbilisi, the capital city of Georgia, on 22nd January 2020.
Biologics being considered as a novel therapy in this region, the launch event attracted more than 50 plus key opinion leaders from the fields of Rheumatology and Haematology. Hetero Biopharma’s Knowledge sharing initiative “KBB” (Knowledge Beyond Borders) utilized this opportunity in providing insights on biosimilars in the treatment of cancer and other challenging diseases.
Dr. Vikram Shetty, GM – Medico Marketing & Clinical Affairs, Hetero Biopharma, addressed a full-fledged session on how Biosimilars has been helping the doctors and patients to meet the unmet needs. He further elaborated on the usage of Rituximab in multiple Leukemias and Rheumatoid arthritis.
Mr. Vinod, Manager – Biologics Business, gave an overview of Hetero’s legacy and its leadership in ARVs and emphasized on Hetero Biopharma’s efforts in developing biosimilars as a dependable option in the treatment of chronic ailments.
The event was well-organized by Mr. Arun Menon and Mr. Ananth Pandya, Directors of Zandra Lifesciences, along with their team members. The technical and marketing communication support was provided by Dr. A V Jayapala Reddy, AVP & Global Head – Biologics Business, and his team member Mr. Sharath Devalapelly, Asst. Manager – Marketing.
In line with our philosophy of REACHing every needy patient, this launch of the biosimilar in Georgia will help Hetero Biopharma to strengthen its global presence in emerging markets.